WILMINGTON, DEL. (CN) - Eighteen states and the District of Columbia claim Abbott Laboratories illegally blocked generic competition through sham patent litigation and reformulating its cholesterol drug TriCor with only minor changes. Florida is lead complainant in this federal antitrust complaint.
Read the Top 8
Sign up for the Top 8, a roundup of the day's top stories delivered directly to your inbox Monday through Friday.